The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Be nice to see the ST and currant bun coverage of hVIVO picked up by FT tomorrow - same media group ?
Agree Jimzi,
Getting a universal flu Vax was a real ā holy grailā when I was at Sanofi and the issue of course is predicting in advance Which field strains are going to be the threat so for 20/21 the 3 strains are.
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/biologics-working-party-bwp-ad-hoc-influenza-working-group-amended-european-union-recommendations/2021_en.pdf
If you did not need to predict in advance these strains and had a Vax that worked against all mutations and antigenic strains just consider how much of a milestone this would be and yes phase 3 ready.
Is the article in the print addition in the UK
Not in the Irish version
Ivy, as you say
Similarly having a Tier 1 client list plus experts like John Oxford is paramount in getting external validation of universal flu Vax as the key players like Merck,Sanofi,GSK,AZNetc will be well aware of ORPH.
Its oven ready for P3 and it would be near negligent if they were not looking at Flu-v very seriously and now - many realise covid plus annual flu could be dire.
And when CF pulls it out of the bag, it won't be a 100% spike but a 100% re-rate.
Yes the ST article a very nice reminder of some of the excellent facilities ORPH have.
One point to remind ourselves is to emphasise the importance of these facilities in the current environment.
Given the fact that community infection of Covid 19 is very low many of the potential treatments such as Vax or therapeutics need to initially tested by challenge to enable them to begin phase 1 trials.
Yes you canāt do this in large numbers but the unique nature of these facilities means that pharma will have little choice if they want to do U.K. based trials.
It will generate revenue but main benefit is the enhanced raising of ORPH profile amongst pharma community which is critical in doing other deals.
Similarly having a Tier 1 client list plus experts like John Oxford is paramount in getting external validation of universal flu Vax as the key players like Merck,Sanofi,GSK,AZNetc will be well aware of ORPH